South San Francisco, CA · Founded 2018 · Privately Held (backing)
Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. TRexBio is based in South San Francisco, CA and was founded in 2018. It is valued at about $274 million as of Oct 2026, set by institutional fund marks. It has raised $222 million.
PMV mark · valuation
$274.0M
Oct 2026
Priced at
—
Total raised
$222.1M
Last round
—
Cap table — not yet on record
TRexBio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
